Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...

Low risk stocks, as gauged by the equity beta, are usually found in sectors like consumer ... 218 percentage points (see more details here). Eli Lilly and Company (NYSE:LLY) is a global ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases ...

Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily ...

Explore Xeris Biopharma's revenue growth, promising pipeline, & thriving products. Learn about their strong outlook & ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

Scientists working for pharmaceutical firm Eli Lilly found that, in 3,000 patients given the drug over the course of three years, the monthly jab more than doubled the risk of a deadly condition ...